The natural history of cystic fibrosis liver disease a prospective cohort study

被引:5
作者
Rowland, Marion [1 ,2 ]
Drummond, Jennifer [1 ,2 ]
Connolly, Lucy [1 ,2 ]
Daly, Erika [3 ]
McCormick, P. Aiden [1 ,4 ]
Bourke, Billy [1 ,5 ,6 ,7 ]
机构
[1] Univ Coll Dublin, Sch Med, Dublin 4, Ireland
[2] Catherine McAuley Clin Res Ctr, Nelson St, Dublin 7, Ireland
[3] D&D Stat Dublin, Dublin, Ireland
[4] St Vincents Univ Hosp, Elm Pk, Dublin 4, Ireland
[5] Childrens Hlth Ireland Crumlin, Dublin 12, Ireland
[6] Natl Childrens Res Ctr, Dublin 12, Ireland
[7] Univ Coll Dublin Belfield, Conway Inst Biomol & Biomed Sci, Dublin 4, Ireland
[8] Woodview House, Dublin 4, Ireland
关键词
Cystic fibrosis liver disease; Nonspecific cystic fibrosis liver disease; Epidemiology; Outcome; Incidence; Children; TRANSIENT ELASTOGRAPHY; AGE; PREVALENCE; MANAGEMENT; DIAGNOSIS; CIRRHOSIS; CHILDREN; VALUES; APRI; RISK;
D O I
10.1016/j.jcf.2023.07.002
中图分类号
R56 [呼吸系及胸部疾病];
学科分类号
摘要
Background: Our understanding of the natural history of cystic fibrosis liver disease (CFLD) is limited, leading to uncertainty for patients their families and clinicians when liver abnormalities are identified.Aim: to determine the incidence of CFLD, identify risk factors and document the natural history of liver abnormalities in cystic fibrosis (CF).Methods: The Irish longitudinal study of CFLD (ILSCFLD) prospectively enrolled 95% of children with CF in 2007. Their liver disease status was classified as (i) advanced liver disease with portal hypertension (CFLD). (ii) nonspecific cystic fibrosis liver disease (NSCFLD) (iii) no liver disease (NoLD)Results: 480/522 (91.9%) children were followed for a median 8.53 years IQR 1.28, of whom 35 (7.29%) had CFLD, 110 (22.9%) NSCFLD and 335 (69.79%) had NoLD. At follow-up 28/445 (6.29%) participants without CFLD at baseline, progressed to CFLD (Incidence 7.51/1000 person years (Pyrs) (95%CI 4.99-10.86). Of these 25/28(89.28%) were <10 years. No participant >10 years of age without clinical or radiological evidence of liver disease at baseline progressed to CFLD.During follow-up 18/35(51.43%) participants with CFLD died or received a transplant, MTx rate 7.75/100 Pyrs (95%CI 4.59-12.25) compared to NSCFLD 2.33/100 Pyrs (95%CI 1.44-3.56) and NoLD 1.13/100 Pyrs (95%CI 0.77-1.59). CFLD was an independent risk factor for mortality in CF. Children with CFLD also had a shorter life expectancy.Conclusion: The incidence of CFLD was highest in children under10 years. Children over10 years, with normal hepatic function did not develop CFLD. Research to identify the cause and improve outcome should focus on young children.
引用
收藏
页码:1054 / 1061
页数:8
相关论文
共 34 条
  • [1] [Anonymous], 2007, Cystic Fibrosis Registry of Ireland Annual Report 2007
  • [2] Cystic Fibrosis Liver Disease: Outcomes and Risk Factors in a Large Cohort of French Patients
    Boelle, Pierre-Yves
    Debray, Dominique
    Guillot, Loic
    Clement, Annick
    Corvol, Harriet
    [J]. HEPATOLOGY, 2019, 69 (04) : 1648 - 1656
  • [3] Prospective comparison of transient elastography, fibrotest, APRI, and liver biopsy for the assessment of fibrosis in chronic hepatitis C
    Castéra, L
    Vergniol, J
    Foucher, J
    Le Bail, B
    Chanteloup, E
    Haaser, M
    Darriet, M
    Couzigou, P
    De Lédinghen, V
    [J]. GASTROENTEROLOGY, 2005, 128 (02) : 343 - 350
  • [4] Closing the Gaps in Pediatric Laboratory Reference Intervals: A CALIPER Database of 40 Biochemical Markers in a Healthy and Multiethnic Population of Children
    Colantonio, David A.
    Kyriakopoulou, Lianna
    Chan, Man Khun
    Daly, Caitlin H.
    Brinc, Davor
    Venner, Allison A.
    Pasic, Maria D.
    Armbruster, David
    Adeli, Khosrow
    [J]. CLINICAL CHEMISTRY, 2012, 58 (05) : 854 - 868
  • [5] Liver disease in cystic fibrosis: A prospective study on incidence, risk factors, and outcome
    Colombo, C
    Battezzati, PM
    Crosignani, A
    Morabito, A
    Costantini, D
    Padoan, R
    Giunta, A
    [J]. HEPATOLOGY, 2002, 36 (06) : 1374 - 1382
  • [6] Cystic fibrosis-related liver disease: Clinical presentations, diagnostic and monitoring approaches in the era of CFTR modulator therapies
    Dana, Jeremy
    Debray, Dominique
    Beaufrere, Aurelie
    Hillaire, Sophie
    Fabre, Monique
    Reinhold, Caroline
    Baumert, Thomas F.
    Berteloot, Laureline
    Vilgrain, Valerie
    [J]. JOURNAL OF HEPATOLOGY, 2022, 76 (02) : 420 - 434
  • [7] Best practice guidance for the diagnosis and management of cystic fibrosis-associated liver disease
    Debray, Dominique
    Kelly, Deirdre
    Houwen, Roderick
    Strandvik, Birgitta
    Colombo, Carla
    [J]. JOURNAL OF CYSTIC FIBROSIS, 2011, 10 : S29 - S36
  • [8] Cirrhosis and other liver disease in cystic fibrosis
    Flass, Thomas
    Narkewicz, Michael R.
    [J]. JOURNAL OF CYSTIC FIBROSIS, 2013, 12 (02) : 116 - 124
  • [9] Reproducibility of transient elastography in the evaluation of liver fibrosis in patients with chronic liver disease
    Fraquelli, Mirella
    Rigamonti, Cristina
    Casazza, Giovanni
    Conte, Dario
    Donato, Maria Francesca
    Ronchi, Guido
    Colombo, Massimo
    [J]. GUT, 2007, 56 (07) : 968 - 973
  • [10] Performance of transient elastography for the staging of liver fibrosis: A meta-analysis
    Friedrich-Rust, Mireen
    Ong, Mei-Fang
    Martens, Swantje
    Sarrazin, Christoph
    Bojunga, Joerg
    Zeuzem, Stefan
    Herrmann, Eva
    [J]. GASTROENTEROLOGY, 2008, 134 (04) : 960 - 974